RET and osteosarcoma: Unlike cisplatin chemoresistance in osteosarcoma, where GFRα1 regulates autophagy independent of the proto-oncogene RET kinase 44, RET was recognized as a functional driver of BTZ resistance in osteogenic sarcoma, suggesting RET as a target for the treatment of advanced osteosarcoma.